Validation of Urinary CXCL10 As a Marker of Borderline, Subclinical, and Clinical Tubulitis

Background. Renal allograft injury secondary to subclinical and clinical tubulitis remains an important cause of allograft fibrosis and loss despite modern immunosuppression. The goal of this study was to validate the previously reported use of urinary CXCL10 (interferon-&ggr;-induced protein of 10 kDa) as a noninvasive marker of tubulitis in an independent clinical cohort. Methods. Urine samples (n=102) from 91 patients with protocol or indication biopsies were assayed for urinary CXCL10 using ELISA. The groups analyzed were as follows: normal histology (n=22); interstitial fibrosis and tubular atrophy (IFTA) (n=20); IFTA and borderline tubulitis (n=13); borderline (n=13), subclinical (n=17); and clinical tubulitis (n=17) without IFTA. Results. The ratio of urinary CXCL10 to creatinine (CXCL10: Cr) was found to distinguish borderline, subclinical and clinical tubulitis from normal histology, and IFTA. The area under the curve receiver operating characteristic curve to distinguish normal versus borderline and subclinical tubulitis was 0.845 (OR 1.407, P=0.0184); normal versus borderline, subclinical and clinical tubulitis was 0.835 (OR 1.400, P=0.0127). CXCL10: Cr demonstrated a sensitivity of 73.3% and specificity of 72.7% for normal versus borderline and subclinical tubulitis at a cut-off of 1.97 ng CXCL10/mmol Cr. Conclusion. This study validates urinary CXCL10 as a noninvasive, sensitive, and specific marker for tubulitis in an independent cohort. The straightforward urine processing is accessible to clinical laboratories. We propose that CXCL10 may be useful as a supplementary noninvasive screening test for tubulitis in renal transplant patients, with a level more than 1.97 ng CXCL10/mmol Cr being a threshold to consider biopsy.

[1]  D. Rush,et al.  Histological findings in early routine biopsies of stable renal allograft recipients. , 1994, Transplantation.

[2]  C. Mackay,et al.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. , 1998, The Journal of clinical investigation.

[3]  P. Nickerson,et al.  Beneficial effects of treatment of early subclinical rejection: a randomized study. , 1998, Journal of the American Society of Nephrology : JASN.

[4]  W. Hancock,et al.  Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection , 2000, The Journal of experimental medicine.

[5]  A. Luster,et al.  Donor-Derived Ip-10 Initiates Development of Acute Allograft Rejection , 2001, The Journal of experimental medicine.

[6]  M. Dziejman,et al.  IFN-γ-Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking1 , 2002, The Journal of Immunology.

[7]  R. Fairchild,et al.  Chemokines: directing leukocyte infiltration into allografts. , 2002, Current opinion in immunology.

[8]  J. Ingelfinger,et al.  Heme: a novel inducer of MCP-1 through HO-dependent and HO-independent mechanisms. , 2003, American journal of physiology. Renal physiology.

[9]  B. Aizenstein,et al.  Elevation of CXCR3‐Binding Chemokines in Urine Indicates Acute Renal‐Allograft Dysfunction , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  Hyoung-Tae Kim,et al.  Surveillance of Acute Rejection in Baboon Renal Transplantation by Elevation of Interferon-&ggr; Inducible Protein-10 and Monokine Induced by Interferon-&ggr; in Urine , 2004, Transplantation.

[11]  M. Salvadori,et al.  High Pretransplant Serum Levels of CXCL10/IP‐10 Are Related to Increased Risk of Renal Allograft Failure , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  V. Sharma,et al.  Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. , 2004, Kidney international.

[13]  Sergio Romagnani,et al.  CXC chemokines: the regulatory link between inflammation and angiogenesis. , 2004, Trends in immunology.

[14]  M. Sho,et al.  A Novel Small-Molecule Compound Targeting CCR5 and CXCR3 Prevents Acute and Chronic Allograft Rejection , 2005, Transplantation.

[15]  M. Salvadori,et al.  High CXCL10 Expression in Rejected Kidneys and Predictive Role of Pretransplant Serum CXCL10 for Acute Rejection And Chronic Allograft Nephropathy , 2005, Transplantation.

[16]  Helmut Geiger,et al.  Prediction of Acute Renal Allograft Rejection by Urinary Monokine Induced by IFN-γ (MIG) , 2005 .

[17]  H. Volk,et al.  Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. , 2006, Kidney international.

[18]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[19]  D. Rush,et al.  Lack of Benefit of Early Protocol Biopsies in Renal Transplant Patients Receiving TAC and MMF: A Randomized Study , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  O. Dormond,et al.  Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells. , 2007, American journal of physiology. Renal physiology.

[21]  Jingwu Z. Zhang,et al.  A New Approach to the Blocking of Alloreactive T Cell-Mediated Graft-versus-Host Disease by In Vivo Administration of Anti-CXCR3 Neutralizing Antibody1 , 2008, The Journal of Immunology.

[22]  M. Streiff,et al.  The Chemokine Receptor Cxcr3 Is Not Essential for Acute Cardiac Allograft Rejection in Mice and Rats , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  X. Hong,et al.  Unaltered Graft Survival and Intragraft Lymphocytes Infiltration in the Cardiac Allograft of Cxcr3−/‐ Mouse Recipients , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  F. Simons,et al.  Ultrasensitive ELISA for measurement of human cytokine responses in primary culture. , 2008, Methods in molecular medicine.

[25]  G. Einecked,et al.  Banff 07 Classification of Renal Allograft Pathology : Updates and Future Directions , 2008 .

[26]  R. Fairchild,et al.  CXCR3 Antagonism Impairs the Development of Donor-Reactive, IFN-&ggr;-Producing Effectors and Prolongs Allograft Survival , 2009, Transplantation.

[27]  P. Nickerson,et al.  Urinary CXCL9 and CXCL10 Levels Correlate with the Extent of Subclinical Tubulitis , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  S. Steavenson,et al.  An antibody to IP-10 is a potent antagonist of cell migration in vitro and in vivo and does not affect disease in several animal models of inflammation , 2009, Autoimmunity.

[29]  M. Stegall,et al.  Identifying Specific Causes of Kidney Allograft Loss , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  P. Nickerson,et al.  Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case-control study. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  B. Aizenstein,et al.  Noninvasive Detection of Acute and Chronic Injuries in Human Renal Transplant by Elevation of Multiple Cytokines/Chemokines in Urine , 2009, Transplantation.

[32]  P. Nickerson,et al.  Early Urinary CCL2 is Associated With the Later Development of Interstitial Fibrosis and Tubular Atrophy in Renal Allografts , 2010, Transplantation.